Overview

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Status:
NOT_YET_RECRUITING
Trial end date:
2034-01-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
Phase:
PHASE3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
remibrutinib